Excessive left ventricular hypertrophy in moderate degenerative aortic stenosis : an ineffective compensatory mechanism triggered by primary myocardial dysfunction and enhanced by concomitant mild renal impairment? by Długosz, Dorota et al.
www.kardiologiapolska.pl
Kardiologia Polska 2018; 76, 10: 1486–1488; DOI: 10.5603/KP.a2018.0196
SHORT COMMUNICATION
Address for correspondence: 
Andrzej Surdacki, MD, PhD, 2nd Department of Cardiology, Faculty of Medicine, Jagiellonian University Medical College, ul. Kopernika 17,  
31–501 Kraków, Poland, tel/fax: +48 12 424 71 80, e-mail: surdacki.andreas@gmx.net
Received: 7.08.2018 Accepted: 29.08.2018 Available as AoP: 17.09.2018
Kardiologia Polska Copyright © Polish Cardiac Society 2018
Excessive left ventricular hypertrophy  
in moderate degenerative aortic stenosis:  
an ineffective compensatory mechanism  
triggered by primary myocardial dysfunction  
and enhanced by concomitant mild  
renal impairment?
Dorota Długosz1, Klaudiusz Bolt1, Wai S. Sam1, Tomasz Nawara1, Olga Kruszelnicka2*,  
Bernadeta Chyrchel3*, Andrzej Surdacki3*
1Students’ Scientific Group at the 2nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland
2Department of Coronary Artery Disease and Heart Failure, John Paul II Memorial Specialist Hospital, Krakow, Poland
32nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland
*Joint senior authors on this work (SSG tutors)
INTRODUCTION
Recent progress has been focused on the management of 
severe degenerative aortic stenosis (AS), while its antecedent, 
moderate AS, still poses a clinical challenge due to the consid-
erable impact of non-valvular factors on its pathophysiology 
and presentation [1]. Importantly, the prognosis in moderate 
AS is worse than commonly assumed [2]. 
Left ventricular (LV) hypertrophy (LVH) develops gradually 
in moderate AS and has traditionally been perceived as an 
adaptive mechanism to preserve LV systolic function. How-
ever, in hypertension [3, 4] and AS [5, 6], inappropriately high 
LV mass (iLVM), i.e. an excess of LV mass (eLVM) greater than 
28% to 35% of the theoretical LV mass (LVM) predicted from 
the individual haemodynamic load in a reference population 
[3, 4], was associated with adverse outcome and depressed 
afterload-corrected LV midwall fractional shortening (mwFS). 
The latter is a better index of LV performance than ejection 
fraction (EF) that overestimates LV function in concentric 
LVH [7]. 
Although the prevalence of iLVM was increasingly high 
and was associated with deteriorating renal function in chronic 
kidney disease (CKD) and hypertension [8, 9], patients with 
renal disease had been excluded from key reports on deter-
minants and prognostic value of iLVM in AS [5, 6]. Thus, our 
aim was to assess relations between renal function, eLVM, and 
mwFS in real-world patients with moderate AS. 
METHODS
We retrospectively analysed medical records of 150 consecu-
tive patients diagnosed with moderate AS (aortic valve area 
[AVA] 1.0–1.5 cm2) [10] at discharge, who where hospitalised 
in a cardiology department. Seventy patients in a stable 
clinical condition entered the final analysis. The exclusion 
criteria included more than mild aortic regurgitation or dis-
ease of another valve, atrial fibrillation, EF < 40%, unstable 
in-hospital serum creatinine level, glomerular filtration rate 
(GFR) < 15 mL/min/1.73 m2 estimated by the CKD-EPI 
formula, and relevant non-cardiac comorbidities (except for 
well-controlled diabetes).
The study protocol was approved by the Ethics 
Committee of the Jagiellonian University (approval no. 
122.6120.228.2016).
Based on data extracted from in-hospital echocar-
diographic records, we calculated the LVM (by modified 
Devereux formula), relative LV wall thickness (RWT), and 
mwFS (assuming a constant LV wall volume throughout the 
cardiac cycle [7]). From echocardiography and averaged 
in-hospital blood pressure (BP), circumferential end-systolic 
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LV wall stress (cESS) [7], valvulo-arterial impedance, a joint 
estimate of valvular and arterial factors that oppose ven-
tricular ejection (Zva [mmHg/mL/m2] = (systolic BP + mean 
aortic gradient) / stroke volume index) [11], and eLVM were 
computed. The latter is a percentage deviation from the pre-
dicted LVM, where LVMpredicted [g] = 55.37 + {6.63 × (height 
[m])2.7} + {0.009216 × (stroke volume [mL]) × (systolic 
BP + peak aortic gradient [mmHg])} − (18.1 × n), with 
n = 1 for men and n = 2 for women [3–6]. 
Statistical analysis 
Patients’ characteristics were compared according to the 
categories of GFR (derived from averaged measurements 
of serum creatinine during the index hospitalisation by the 
CKD-EPI formula: group A [GFR > 85], B [GFR: 60–85], and C 
[GFR: 15–59]) by analysis of variance (ANOVA), Kruskal-Wallis 
ANOVA, or c2 test, and trend effects were determined by 
Spearman’s coefficients. Additionally, semi-standardised 
regression coefficients (b) were computed for univariate and 
multivariate predictors of eLVM and mwFS, using multiple 
linear ridge regression due to collinearity between candidate 
predictors, including age, sex, coronary artery disease, GFR, 
AVA, Zva, cESS, and RWT. A p-value < 0.05 was assumed 
as significant. 
RESULTS AND DISCUSSION
Excess of LVM and age increased gradually across decreas-
ing GFR categories (Table 1; Suppl. Table S1; Suppl. Fig. S1 
— see journal website). Compared to group A, subjects from 
groups B and C had significantly higher systolic BP, RWT, and 
LVM/volume ratio (Suppl. Fig. S2 — see journal website), 
and lower LV mwFS (Suppl. Fig. S3 — see journal website), 
all of which were similar in patients from groups B and C (Table 1).
After Bonferroni correction for multiple comparisons, 
eLVM was positively associated with age, Zva, RWT, and 
LVM/volume ratio and inversely with GFR, mwFS, and cESS. 
Also, mwFS correlated negatively with RWT and LVM/volume 
ratio (all unadjusted p-values ≤ 0.001) (Suppl. Table S2 — see 
journal website).
In multivariate analysis, the inverse eLVM–mwFS 
relationship was strengthened, and eLVM was associ-
ated only with mwFS (b = –36 ± 6, p < 0.001) and cESS 
(b = –29 ± 6, p < 0.001), whereas mwFS was related to 
eLVM (b = –2.6 ± 0.4, p < 0.001) and cESS (b = –1.9 ± 0.4, 
p < 0.001). Substitution of LVM/volume ratio for RWT did 
not change the results.
We found that progressive early GFR decline coincided 
with increasing eLVM and reduced mwFS in moderate AS. 
Importantly, upon multivariate adjustment, these associations 
lost their significance, while the inverse eLVM–mwFS rela-
tionship was further strengthened. Additionally, body mass 
index, previously linked to iLVH [4, 6], was similar across 
groups A–C. As AVA, cESS, and LV end-diastolic diameter 
(a raw estimate of LV preload) were similar irrespective of 
GFR, we hypothesised that gradual development of exces-
sive LVH could be triggered by load-independent primary 
myocardial dysfunction and amplified by coexistent renal 
impairment. This mechanism might keep cESS relatively 
constant despite disease progression, but does not ensure the 
restoration of LV performance, which may explain progres-
sive eLVM increase across groups A–C and similar reduction 
in mwFS in groups B and C vs. A. 
Table 1. Echocardiographic characteristics, left ventricular (LV) afterload, and excess of LV mass according to glomerular filtration 
rate (GFR)
Characteristic GFR [mL/min/1.73 m2] p p for trend
> 85
(n = 18)
60–85
(n = 30)
15–59
(n = 22)
Aortic valve area [cm2] 1.2 ± 0.1 1.2 ± 0.1 1.2 ± 0.2 0.5 0.8
LV diastolic diameter [cm] 5.1 ± 0.7 4.9 ± 0.6 4.9 ± 0.7 0.7 0.5
LV mass [g] 178 ± 49 203 ± 45 207 ± 60 0.2 0.15
LV mass/volume ratio [g/mL] 1.49 ± 0.38 1.85 ± 0.46* 1.85 ± 0.50* 0.02 0.04
Relative LV wall thickness 0.42 ± 0.09 0.49 ± 0.10* 0.49 ± 0.10* 0.04 0.07
Ejection fraction [%] 61 ± 8 59 ± 7 60 ± 6 0.7 0.9
LV midwall fractional shortening [%] 17 ± 3 14 ± 4* 15 ± 4* 0.03 0.12
cESS [hPa] 181 ± 65 147 ± 69 163 ± 65 0.4 0.4
Valvulo-arterial impedance [mmHg/mL/m2] 4.2 ± 1.4 5.4 ± 2.6 5.0 ± 1.5 0.15 0.1
Excess of LV mass [%] –2 (–6–13) 21 (1–57)* 61 (–18–85)* 0.03 0.01 
Data are shown as mean ± standard deviation or median (interquartile range). cESS — circumferential end-systolic LV wall stress
*p < 0.05, vs. GFR > 85 mL/min/1.73 m2 by post-hoc Fisher test or Mann-Whitney test.
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The concept of iLVM in AS a compensatory (albeit inef-
fective) mechanism evoked by depressed LV contractility, not 
elevated LV afterload, was first proposed by Italian research-
ers, who found lower mwFS for each given level of cESS in 
patients with iLVM [5, 6], in analogy to hypertension [3, 4]. 
However, patients with renal disease had been excluded from 
those AS studies [5, 6]. Thus, our results supplement an earlier 
report of increasingly high prevalence of iLVM and associated 
depressed mwFS along CKD stages 2–5, beginning at mild 
renal dysfunction [9] in mainly hypertensive subjects without 
coexisting AS. Therefore, our study is the first to show early 
renal impairment as a contributor to eLVM in AS.
Because eLVM independently predicted adverse outcome 
in severe AS [5], it seems to be a potential therapeutic target. 
However, renin-angiotensin system inhibitors (RASI), a main-
stay for nephroprotection and LVH inhibition, are frequently 
avoided in AS due to fear of hypotension. Nevertheless, the 
use of RASI was associated with the lack of adverse prognos-
tic effects and slower LVM progression in mild-to-moderate 
AS [12]. 
In conclusion, early renal impairment enhances excessive 
LVH that appears secondary to subtle, load-independent LV 
systolic dysfunction. Prevention of early kidney deterioration 
in less-than-severe AS may slow development of excessive 
LVH and improve long-term prognosis. 
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